MKP 10241 / Mankind Pharma - LARVOL DELTA

Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders. (PubMed, J Med Chem) - "MKP10241 was evaluated in preclinical toxicity and genotoxicity studies in rats and dogs and found safe. Considering the preclinical safety and efficacy profile, MKP10241 has been advanced for safety, tolerability, and pharmacokinetic evaluation in healthy volunteers in a Phase-I clinical trial."

Journal • Diabetes • Dyslipidemia • Fibrosis • Genetic Disorders • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes (clinicaltrials.gov) - P2 | N=68 | Recruiting | Sponsor: Mankind Pharma Limited | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Sep 2025 ➔ Jan 2026

Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes (clinicaltrials.gov) - P2 | N=68 | Not yet recruiting | Sponsor: Mankind Pharma Limited

New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus